Pieris Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Good afternoon, everyone, and thank you for joining us on day four of the virtual Cantor healthcare conference. My name is Emma Nealon, and I'm one of the small/mid-cap biotech analysts here at Cantor. And it's my pleasure to introduce our next presenting company, Pieris Pharmaceuticals. Joining us today from Pieris is CEO Stephen Yoder. Steve, I'll turn it over to you to take us through the story.
Thank you very much, Emma, and thanks as well to Cantor for the invitation and the opportunity to present Pieris Pharmaceuticals to you all today. For those of you who don't know much about Pieris, or anything about Pieris, you can think of us as a large molecule R&D company, and I'm happy to share the story with you today. We've had a great first half of the year and looking at a lot of opportunities over the next couple of quarters. As I share the story with you today, I will be making forward-looking statements, so of course, you can consult our disclaimer.
And
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |